PALLADIO BIOSCIENCES
Palladio Bio is a clinical-stage company developing transformative medicines for orphan diseases of the kidney. The company specializes in the fields of biotechnology, pharmaceutical. and therapeutics. Its products are designed for renal disease, kidney disease, and polycystic kidney disease. The company was founded in 2015 and headquartered in Horsham, Pennsylvania.
PALLADIO BIOSCIENCES
Industry:
Biotechnology Pharmaceutical Therapeutics
Founded:
2015-01-01
Address:
Horsham, Pennsylvania, United States
Country:
United States
Website Url:
http://www.palladiobio.com
Total Employee:
1+
Status:
Active
Total Funding:
20 M USD
Technology used in webpage:
SPF Microsoft Exchange Online Amazon Office 365 Mail GoDaddy DNS AWS Global Accelerator
Similar Organizations
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Axcella
Axcella is a biotechnology company that treats diseases using endogenous metabolic modulators.
Current Advisors List
Board_member
Board_member
Board_member
Current Employees Featured
Lorenzo Pellegrini CEO & founder @ Palladio Biosciences
CEO & founder
Neil Shusterman Chief Medical Officer @ Palladio Biosciences
Chief Medical Officer
Linda Hogan Chief Business Officer @ Palladio Biosciences
Chief Business Officer
2016-10-01
Founder
Investors List
Samsara BioCapital
Samsara BioCapital investment in Series B - Palladio Biosciences
OUP (Osage University Partners)
OUP (Osage University Partners) investment in Series B - Palladio Biosciences
Roche Venture Fund
Roche Venture Fund investment in Series B - Palladio Biosciences
Medicxi
Medicxi investment in Series B - Palladio Biosciences
Medicxi
Medicxi investment in Series A - Palladio Biosciences
Official Site Inspections
http://www.palladiobio.com
- Host name: 104.21.49.181
- IP address: 104.21.49.181
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Palladio Biosciences"
Palladio Biosciences - Crunchbase Company Profile & Funding
Organization. Palladio Biosciences . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. ... Contact Email …See details»
Palladio Biosciences - PitchBook
Palladio Biosciences General Information Description. Developer of novel therapeutics designed to offer medicines for orphan drug diseases of the …See details»
Palladio Biosciences - Craft
Palladio Biosciences is a company developing medicines for orphan diseases of the kidney. Its lead product, lixivaptan, a selective vasopressin V2 receptor antagonist for the treatment of …See details»
Palladio Biosciences - Contacts, Employees, Board Members, …
Organization. Palladio Biosciences . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 3. Number of …See details»
Palladio Biosciences - Org Chart, Teams, Culture & Jobs - The Org
View Palladio Biosciences' up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more.See details»
Palladio Biosciences - Funding, Financials, Valuation & Investors
Palladio Biosciences develops transformative medicines for orphan diseases of the kidney.See details»
Palladio Biosciences - VentureRadar
Similar Companies: AceLink Therapeutics USA Privately Held Founded in 2019, AceLink Therapeutics is an innovative biopharma startup focusing on developing safe and effective …See details»
Palladio Biosciences CEO and Key Executive Team | Craft.co
Palladio Biosciences's Chief Executive Officer & Director is Alex Martin. Other executives include Lorenzo Pellegrini, Founder, Director and Chief Operating Officer; Marella Thorell, Chief …See details»
Palladio Biosciences - Centessa Therapeutics (NASDAQ:CNTA)
Palladio Bio is a clinical stage company developing transformative medicines for orphan diseases of the kidney. The company’s lead drug is the vasopressin V2 receptor antagonist lixivaptan …See details»
Palladio Biosciences Receives FDA IND Clearance to …
May 8, 2018 Palladio Biosciences Receives FDA IND Clearance to Begin the ELISA Study, a Phase 2 Clinical Trial with Lixivaptan in Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)See details»
Palladio Biosciences Appoints Alex Martin Chief …
Aug 8, 2019 Palladio Biosciences, Inc. Linda Hogan, +1 908-294-8728 lhogan@palladiobio.com Release Summary Palladio Biosciences Leadership Team expands with appointment of Alex Martin as CEO.See details»
Palladio Receives Orphan Drug Designation From The FDA For
Oct 4, 2017 NEWTOWN, Pa.--(BUSINESS WIRE)--Palladio Biosciences, Inc. (Palladio), a privately held biopharmaceutical company founded to develop medicines that make a …See details»
Palladio Biosciences Appoints Neil H. Shusterman, M.D., as Chief ...
Jan 3, 2019 Palladio Biosciences, Inc. Linda Hogan, +1-908-294-8728 lhogan@palladiobio.com Release Summary Dr. Neil H. Shusterman joins Palladio Biosciences as Chief Medical OfficerSee details»
Palladio grabs $20M to take once-discarded drug through phase 3
Sep 25, 2020 Palladio Biosciences has raised a $20 million series B round. The financing, which attracted support from Roche Venture Fund and Medicxi, sets Palladio up to test its …See details»
Palladio Biosciences Formed to Develop Transformative Medicines …
May 23, 2017 Palladio Biosciences, Inc. Linda Hogan, +1 908-294-8728 lhogan@palladiobio.com Release Summary Palladio Biosciences, newly formed start up, …See details»
Palladio Biosciences Announces Dosing of First ... - Pipelinereview
Dec 20, 2018 For more information, please visit www.palladiobio.com. About the PKD Foundation: The PKD Foundation is the only organization in the U.S. solely dedicated to …See details»
Palladio Biosciences Receives FDA IND Clearance to Begin the
May 8, 2018 Palladio Biosciences Receives FDA IND Clearance to Begin the ELISA Study, a Phase 2 Clinical Trial with Lixivaptan in Patients with Autosomal Dominant Polycystic Kidney …See details»
Palladio Biosciences Announces Dosing of First Patients with
Dec 18, 2018 Palladio Biosciences Announces Dosing of First Patients with Lixivaptan in ELiSA, a Phase 2 Clinical Study in Patients with Autosomal Dominant Polycystic Kidney Disease …See details»
Palladio Completes $20 Million Series B Financing - Business Wire
Sep 25, 2020 Linda Hogan Palladio Biosciences, Inc. 908-294-8728 lhogan@palladiobio.com. Contacts. Linda Hogan Palladio Biosciences, Inc. 908-294-8728 lhogan@palladiobio.com. Site …See details»
Palladio Biosciences Announces Dosing of First Patients with …
Dec 18, 2018 Palladio Biosciences Announces Dosing of First Patients with Lixivaptan in ELiSA, a Phase 2 Clinical Study in Patients with Autosomal Dominant Polycystic Kidney Disease …See details»